Proven and clinically meaningful efficacy data

At week 12

Many moderate to severe HS patients achieved HiSCR.1,3,7
HiSCR requires:

>>> CSS OVERRIDE
≥ 50% reduction in the total abbscess and inflammatory nodule count relative to baseline

with

no increase in abscess count relative to baseline

and

no increase in draining fistula count relative to baseline

Well-studied safety profile

well-studied HUMIRA HS safety

The safety profile of HS was consistent with the safety profile of HUMIRA overall—no new safety signals in adults.1,4,5

Dosing for adults and adolescents (≥12 yrs)

 

  • Once a week dosing schedule following initial doses for adults + adolescents ≥60 kg (132 lbs)1
  • Every-other-week dosing schedule following initial dose for adolescents ≥30kg to <60 kg (66 lbs to <132 lbs)1

 

HUMIRA Citrate-free

No citrate buffers, thinner needle, less pain immediately following injection compared with the HUMIRA 40 mg/0.8 mL presentation.8†§

HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.
§Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.